A Multi-Center Trial to Evaluate the Safety and Toxicity of Nanoxel®-M in Breast Cancer Patients
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Gwak, Geumhee | - |
dc.contributor.author | Chung, Min Sung | - |
dc.contributor.author | Kim, Tae Hyun | - |
dc.contributor.author | Park, Inseok | - |
dc.contributor.author | Kim, Jungbin | - |
dc.contributor.author | Um, Eun Hae | - |
dc.contributor.author | Lee, Anbok | - |
dc.contributor.author | Kim, Jae Il | - |
dc.date.accessioned | 2023-09-18T06:28:46Z | - |
dc.date.available | 2023-09-18T06:28:46Z | - |
dc.date.created | 2023-07-21 | - |
dc.date.issued | 2021-12 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/190615 | - |
dc.description.abstract | Purpose: Nanoxel®-M is a low-molecular-weight, non-toxic, biodegradable, docetaxel-loaded methoxy-poly (ethylene glycol)-block-poly (D,L-lactide) (mPEG-PDLLA) micellar formulation. We conducted a multicenter trial to evaluate the safety and toxicity of Nanoxel®-M and the quality of life (QoL) of Korean breast cancer patients treated with this formulation. Methods: Patients received adjuvant Nanoxel®-M with a schedule comprising four alternating cycles of doxorubicin with cyclophosphamide, followed by either Nanoxel®-M or Nanoxel®-M with cyclophosphamide after surgery for early breast cancer. We analyzed hematological and non-hematological toxicity profiles and alterations in patient QoL using the Korean version of the European organization for research and treatment of cancer core 30-item quality of life questionnaire. Fifty-five operable breast cancer patients with stage II or III disease were enrolled from four centers in Korea. Results: Regarding safety and toxicity profiles, grade 3/4 toxicity presented as anemia in 0.5%, neutropenia in 61.8%, febrile neutropenia in 4.5%, mucositis in 1.4%, and edema in 0.5% of patients during 220 total cycles. However, all-grade thrombocytopenia was not observed among hematological toxicities. No grade 3/4 nausea, vomiting, diarrhea, hand foot syndrome, dyspnea, allergic reaction, edema, or peripheral neuropathy were observed. Furthermore, no vehicle-related hypersensitivity reactions occurred when using Nanoxel®-M. Conclusion: Our findings indicate that Nanoxel®-M could be used to treat operable breast cancer patients, compare favorably with docetaxel in terms of hypersensitivity reactions and the incidence of taxane-induced peripheral neuropathy, and is associated with a similar incidence of febrile neutropenia. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | 한국유방암학회 | - |
dc.title | A Multi-Center Trial to Evaluate the Safety and Toxicity of Nanoxel®-M in Breast Cancer Patients | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Chung, Min Sung | - |
dc.identifier.doi | 10.14449/jbd.2021.9.2.45 | - |
dc.identifier.bibliographicCitation | Journal of Breast Disease, v.9, no.2, pp.45 - 55 | - |
dc.relation.isPartOf | Journal of Breast Disease | - |
dc.citation.title | Journal of Breast Disease | - |
dc.citation.volume | 9 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 45 | - |
dc.citation.endPage | 55 | - |
dc.type.rims | ART | - |
dc.type.docType | 정기학술지(Article(Perspective Article포함)) | - |
dc.identifier.kciid | ART002788190 | - |
dc.description.journalClass | 2 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | kci | - |
dc.subject.keywordAuthor | Breast neoplasms | - |
dc.subject.keywordAuthor | Docetaxel | - |
dc.subject.keywordAuthor | Nanoxel®-M | - |
dc.subject.keywordAuthor | Quality of life | - |
dc.subject.keywordAuthor | Toxicity | - |
dc.identifier.url | https://www.jbd.or.kr/journal/view.php?doi=10.14449/jbd.2021.9.2.45 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.